KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Neogenomics (NEO) Return on Capital Employed (2016 - 2026)

Neogenomics filings provide 16 years of Return on Capital Employed readings, the most recent being 8.38% for Q1 2026.

  • On a quarterly basis, Return on Capital Employed fell 171.0% to 8.38% in Q1 2026 year-over-year; TTM through Mar 2026 was 8.38%, a 171.0% decrease, with the full-year FY2025 number at 8.21%, down 143.0% from a year prior.
  • Return on Capital Employed hit 8.38% in Q1 2026 for Neogenomics, up from 9.06% in the prior quarter.
  • In the past five years, Return on Capital Employed ranged from a high of 6.52% in Q1 2024 to a low of 10.23% in Q3 2022.
  • Median Return on Capital Employed over the past 5 years was 8.23% (2025), compared with a mean of 8.14%.
  • Biggest five-year swings in Return on Capital Employed: tumbled -830bps in 2022 and later skyrocketed 298bps in 2023.
  • Neogenomics' Return on Capital Employed stood at 9.51% in 2022, then grew by 28bps to 6.8% in 2023, then dropped by -1bps to 6.88% in 2024, then crashed by -32bps to 9.06% in 2025, then increased by 8bps to 8.38% in 2026.
  • The last three reported values for Return on Capital Employed were 8.38% (Q1 2026), 9.06% (Q4 2025), and 9.4% (Q3 2025) per Business Quant data.